Nordic investment firm Verdane has acquired a stake in Clue, the women-led period and cycle tracker. The deal provides fresh capital for the Berlin-based health and wellness app, though financial terms remain undisclosed. Clue, founded in 2013, has built a reputation for its science-based approach to menstrual health tracking.

This investment arrives as digital women's health platforms gain serious traction. Clue has long championed reproductive health education and data privacy, standing out in a crowded field of wellness apps. Verdane's backing signals growing institutional confidence in the sector's commercial viability and its potential to move beyond simple tracking into broader healthcare services.

The funding will likely fuel product development and market expansion for Clue. Investors are increasingly viewing menstrual health as a gateway to larger conversations around fertility, menopause, and preventative care. Expect Clue to deepen its medical research partnerships while exploring premium subscription tiers that offer more personalized health insights.